Gene therapy with AdV-IL2 (TG 1021) in unresectable digestive adenocarcinoma. Phase I-II study, first inclusions

Adv Exp Med Biol. 1998:451:527-30. doi: 10.1007/978-1-4615-5357-1_81.
No abstract available

Publication types

  • Clinical Trial
  • Clinical Trial, Phase I
  • Clinical Trial, Phase II

MeSH terms

  • Adenocarcinoma / therapy*
  • Adult
  • Aged
  • Colonic Neoplasms / therapy*
  • Combined Modality Therapy
  • Digestive System Neoplasms / therapy*
  • Female
  • Gene Transfer Techniques
  • Genetic Therapy* / adverse effects
  • Humans
  • Interleukin-2 / biosynthesis
  • Interleukin-2 / genetics*
  • Interleukins / blood
  • Liver Neoplasms / secondary
  • Liver Neoplasms / therapy
  • Male
  • Middle Aged
  • Patient Selection
  • Polymerase Chain Reaction
  • Receptors, Interleukin-2 / biosynthesis
  • Receptors, Interleukin-2 / genetics

Substances

  • Interleukin-2
  • Interleukins
  • Receptors, Interleukin-2